NCT07586332

Brief Summary

The aim of the project is to elucidate the genetic etiology underlying the development of the processus vaginalis (PV) in male children with indirect inguinal hernia (IIH) and undescended testis (UT), through the investigation of potential variants in the INSL3, WT1, and GATA6 genes using next-generation sequencing (NGS), and to explore possible differences in the tissue-level expression of these genes by real-time PCR analysis. Indirect inguinal hernia represents a significant clinical problem for human health, due to its high prevalence in the population and its potential to cause life-threatening conditions or permanent functional loss. The treatment of both of these conditions, under current circumstances, requires surgical intervention. In the course of IIH, segmental loss of reproductive organs and intestines in both girls and boys, together with ischemia-reperfusion injury occurring in these tissues, constitute serious medical complications that cannot be overlooked. Furthermore, the substantial economic cost associated with the management of such severe complications necessitates meticulous control of the process. UT, on the other hand, is being observed with increasing frequency today and represents a significant health problem in society, as it is closely associated with reproductive disorders. Clarifying the mechanisms underlying the pathogenesis of both inguinal region diseases will make a critical contribution not only to protecting individual health, but also to advancing societal well-being and scientific knowledge. Moreover, the data obtained from this study are expected to provide new perspectives for IIH and UT treatment approaches and form a scientific basis for future studies in the field. This prospective cross-sectional study will comprise 20 patients with indirect inguinal hernia, 20 patients with undescended testis, and 20 patients undergoing circumcision, consecutively admitted to the Department of Pediatric Surgery, Faculty of Medicine, Trakya University. Patent processus vaginalis tissues excised during surgery from patients with IIH and UT, and preputial tissues obtained from patients in the circumcision group, will be collected. Tissue and blood samples taken from the patients will be transferred to the Department of Medical Genetics, Faculty of Medicine, Trakya University, for further analyses.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3

participants targeted

Target at below P25 for all trials

Timeline
9mo left

Started Sep 2025

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress48%
Sep 2025Mar 2027

Study Start

First participant enrolled

September 9, 2025

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 10, 2026

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

April 30, 2026

Completed
14 days until next milestone

First Posted

Study publicly available on registry

May 14, 2026

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2027

Expected
Last Updated

May 14, 2026

Status Verified

April 1, 2026

Enrollment Period

7 months

First QC Date

April 30, 2026

Last Update Submit

May 12, 2026

Conditions

Keywords

childreninguinal herniaundescended testisprocessus vaginalisgata6wt1insl3

Outcome Measures

Primary Outcomes (1)

  • Identification of Genetic Variants in INSL3, WT1, and GATA6 Genes

    Investigation of potential genetic variants and mutations in INSL3, WT1, and GATA6 genes using Next-Generation Sequencing (NGS) from both processus vaginalis (PV) tissues and genomic DNA obtained from leukocytes.

    Up to 3 months after completion of the study

Secondary Outcomes (1)

  • Analysis of Gene Expression Levels in Processus Vaginalis Tissues

    Up to 3 months after completion of the study

Eligibility Criteria

AgeUp to 18 Years
Sexmale(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Patients who present to the Pediatric Surgery Outpatient Clinic of Trakya University Faculty of Medicine between September 2025 and September 2026, including 20 diagnosed with IIH, 20 diagnosed with IT, and 20 presenting for circumcision, and for whom informed consent has been obtained, will be consecutively enrolled in the study.

You may qualify if:

  • All pediatric age groups
  • Patients with Indirect Inguinal Hernia without additional systemic or inguinoscrotal diseases
  • Patients with Undescended Testis without additional systemic or inguinoscrotal diseases
  • Patients requesting circumcision without additional systemic or inguinoscrotal diseases
  • Healthy children undergoing circumcision for traditional reasons

You may not qualify if:

  • Patients with recurrence, hydrocele, prior abdominal/inguinoscrotal surgery, genetic disorders, or incarcerated/strangulated IIH
  • Any syndromic disease
  • Bilateral IIH patients
  • Bilateral UT patients
  • Patients with hypospadias, micropenis, disorders of sex development, or genitourinary anomalies/diseases
  • Presence of umbilical, femoral, Spigelian, or lumbar hernia
  • History of premature birth

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Trakya University Faculty of Medicine, Department of Pediatric Surgery

Edirne, 22020, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITH DNA

Patent processus vaginalis and preputial tissue samples for mRNA expression analysis, and peripheral blood samples stored for DNA variation analysis

MeSH Terms

Conditions

Hernia, InguinalCryptorchidismWilms Tumor

Condition Hierarchy (Ancestors)

Hernia, AbdominalHerniaPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsTesticular DiseasesGenital Diseases, MaleGenital DiseasesUrogenital DiseasesMale Urogenital DiseasesUrogenital AbnormalitiesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesGonadal DisordersEndocrine System DiseasesNeoplasms, Complex and MixedNeoplasms by Histologic TypeNeoplasmsKidney NeoplasmsUrologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteNeoplastic Syndromes, HereditaryFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsKidney DiseasesUrologic DiseasesGenetic Diseases, Inborn

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
14 Days
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident

Study Record Dates

First Submitted

April 30, 2026

First Posted

May 14, 2026

Study Start

September 9, 2025

Primary Completion

April 10, 2026

Study Completion (Estimated)

March 1, 2027

Last Updated

May 14, 2026

Record last verified: 2026-04

Locations